NEW YORK, Dec 11 - Rosetta Inpharmatics said Monday that it had licensed its Resolver Expression Data Analysis System to Glaxo Wellcome.

Glaxo Wellcome will use the system, which is exclusively distributed by Agilent Technologies, to to analyze gene expression data.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers hope to tease out the signature effects that different carcinogens leave on the genome to determine their contributions to disease, Mosaic reports.

An Imperial College London-led team reports that it was able to use a gene drive to control a population of lab mosquitos.

The Wall Street Journal looks into the cost of new gene therapies.

In PNAS this week: genomic effects of silver fox domestication, limited effect of mitochondrial mutations on aging in fruit flies, and more.